125 words)
Eggerthella lenta, another prevalent gut Actinobacterium found in >80% of individuals (17) , is enriched in patients with autoimmune diseases (3, 5) , but the impact of this bacterium on host immunity and disease phenotypes remains unexplored. Here, we show that E. lenta is sufficient to increase Th17 cells and exacerbate murine colitis. Through a combination of gnotobiotics, comparative genomics, in vitro assays, and bacterial genetics we identify a single strain-variable gene (cardiac glycoside reductase 2, cgr2) which is necessary and sufficient to increase Th17 cells. These data provide the first physiological function for Cgr2, which was previously implicated in xenobiotic metabolism, inactivating the cardiac drug digoxin and other toxic plant compounds within the cardenolide family (11, 18) . Finally, by leveraging the knowledge that Cgr2 activity is abrogated by high levels of dietary arginine (11, 18) we show that dietary arginine prevents E. lenta-dependent Th17 accumulation and associated colitis emphasizing that diet can affect the capacity of specific bacterial strains to modulate immune responses and downstream disease.
We began by investigating the impact of E. lenta colonization of germ-free (GF) mice on Th17 levels. GF mice gavaged with E. lenta strain DSM 2243 (2243) had increased percentages and numbers of IL-17a+ CD4+ Th17 cells in the small intestine and colon but not spleen ( Figure   1A -C, Sup. Fig 1A and B) . There was no effect on intestinal IFNγ+ CD4+ T cells (Sup. Fig 1C   and D) and qPCR on ileal tissue confirmed an increase in IL-17F without significant changes in Th1 (IFNγ, Tbet), Treg (FoxP3), or other inflammatory markers, with the exception of a slight increase in BCL6, which could indicate an increase in T follicular helper cells (Figure 1D) .
Interestingly, small intestinal IL17a+ TCRγδ+ T cells trended upwards in E. lenta monocolonized mice but Lineage-Rorγt+ CD90+ IL17+ group 3 innate lymphoid cells (ILC3) were not altered (Sup. Fig 1E and F) . To test if E. lenta could augment IL-17 production in the context of a more complex microbiota, we gavaged SPF mice with E. lenta or a media control (BHI) every other day for two weeks and observed a similar accumulation of Th17 cells with E. lenta in the colon and trend towards increased levels in the small intestine (Figure 1E, Sup. Fig   1G and H) .
To investigate whether E. lenta colonization impacts chronic inflammatory and autoimmune mouse models, we induced DSS colitis in GF and E. lenta monocolonized mice.
Mice were colonized 2 weeks prior to disease induction to stimulate Th17 accumulation to assess the impact of this accumulation on disease. E. lenta colonized mice developed more severe disease than their GF counterparts in both disease scores and colon shortening (Figure 2A and   2B ), and colonic Th17 levels were elevated, correlating with colon shortening severity ( Fig. 2C and Sup . Fig 2A-C) . To determine if E. lenta mediated Th17 accumulation was the root of this worsened disease phenotype, we compared Rorc -/and WT SPF mice gavaged with E. lenta or media control every other day for 2 weeks preceding induction of DSS colitis. E. lenta colonized Rorc -/mice had no differences in disease severity compared to the media control while WT mice colonized with E. lenta developed worsened disease compared to control WT mice (Figure 2D and 2E). Colon shortening severity correlated to elevated Th17 levels (Figure 2F-H) . These results suggest that Th17 accumulation by E. lenta contributes to worsened colitis severity in E. lenta colonized mice, although it is important to note that Th17 cells are not the only cell type missing from Rorc -/mice as ILC3 cells are also lacking. However, as previously noted we did not see differences in the ILC3 population in E. lenta colonized mice (Sup. Fig. 1F) , consistent with the hypothesis that Th17 accumulation is responsible for the observed phenotype.
To test whether E. lenta colonization contributes to more severe disease in other models of colitis, we gavaged E. lenta strain 2243 or a media control three times a week into IL-10 -/-SPF mice and weight was tracked. E. lenta gavage resulted in lower percentage of initial weight which correlated with intestinal Th17 levels (Figure 2I and J, Sup. Fig D-F) and prolapse incidence was increased compared to media control ( Figure 2K) suggesting that E. lenta colonization contributes to more severe disease.
We next wanted to investigate if E. lenta mediated Th17 accumulation was a strainvariable phenotype. Therefore, we monocolonized mice with E. lenta strains DSM 2243 (2243), FAA 1-3-56 (1356), DSM 15644 (15644), or heat-killed E. lenta 2243 (see Table S5 for strain information). Viable E. lenta 2243 was the only group which elevated Th17 accumulation compared to GF mice ( Figure 3A and 3B) in both percentage and total number (Sup. Fig. 3) indicating E. lenta mediated Th17 accumulation is strain variable and requires live bacteria.
Next, we tested whether monocolonization with a strain of E. lenta that did not increase Th17 levels would impact DSS colitis. While colonization with E. lenta 2243 again induced more severe colitis, colonization with E. lenta 1356 did not induce more severe disease ( Figure 3C and 3D), consistent with the inability of this strain to increase intestinal Th17 cells to the same extent as E. lenta 2243 (Figure 3E and 3F) .
To more systematically assess the variation between E. lenta strains and their capacity to increase Th17 cells, we turned to an in vitro cell culture assay. Splenic CD4+ T cells were cultured in Th17 skewing conditions with the addition of conditioned media from E. lenta strains or media controls. Recapitulating our in vivo findings, conditioned media from E. lenta 2243 but not 1356 or 15644 significantly increased IL-17a levels compared to media control as assessed by IL-17a ELISA (Figure 4A) . Interestingly, media itself (BHI) decreased IL-17a production, suggesting there may be an uncharacterized factor in our bacterial culture media inhibiting its production.
Having validated our in vitro assay, we tested a broader panel of 10 E. lenta strains (17) for their Th17 accumulation capacity. This screen revealed 6 E. lenta strains that did not increase IL-17a production and 4 strains that significantly increased IL-17a production ( Figure 4B ).
Using the ElenMatchR comparative genomics tool (17) , we determined that a single genomic locus (orthologous gene cluster 4725-4731), was present in all of the strains that increased IL-17a production and missing from all of the strains that did not induce IL-17a ( Figure 4B ).
Interestingly, we had previously implicated this same locus, referred to as the cardiac glycoside reductase (cgr)-associated gene cluster, in the metabolism of the cardiac drug digoxin and other plant toxins from the cardenolide family (18) . These results indicated that one or more of the genes in this locus plays a role in shaping host immunity.
Based on prior evidence that digoxin inhibits Th17 cell differentiation (19, 20) , we hypothesized that the enzyme sufficient for digoxin reduction, Cgr2, may be capable of increasing Th17 cells due to the reduction of an endogenous substrate found in the mouse gut lumen and our cell culture media. A key prediction of this hypothesis is that Cgr2 should be sufficient to promote IL-17a production in our in vitro assay. We used constructs in which WT Cgr2 or a partial loss-of-function natural variant of Cgr2 (Y333N) were expressed in Rhodococcus erythropolis under control of a thiostrepton-inducible promoter (18) . Expression of the WT but not variant form of Cgr2 resulted in a significant increase in IL-17a levels compared to uninduced controls (Figure 4C ). To confirm that Cgr2 expression is also sufficient to increase Th17 cells in vivo, we supplied conditioned media from R. erythropolis strains with WT or Y333N Cgr2 in the presence or absence of the thiostrepton inducer. Only conditioned media from R. erythropolis with induced WT Cgr2 expression resulted in a significant increase in small intestinal Th17 cells (Figure 4D and Sup. Fig. 4 ).
Prior studies have shown that elevated protein intake, likely due to the increased concentration of arginine in the gut lumen, inhibits the ability of Cgr2 to reduce the cardiac drug digoxin (11, 18) . We hypothesized that arginine would have a similar ability to prevent E. lenta mediated Th17 accumulation and associated disease phenotypes. GF, E. lenta strain 2243 (cgr+), or 15644 (cgr-) monocolonized mice were fed a 1% or 3% arginine diet. The 1% and 3% arginine diets had no impact on Th17 levels in the GF or 15644 colonized mice. E. lenta 2243 colonized mice had elevated Th17 cells on the low arginine diet but those levels were decreased back to baseline levels on the high arginine diet (Figure 5A and 5B) . To determine if the effect of arginine levels on E. lenta mediated Th17 accumulation results in altered colitis outcome, we gavaged E. lenta 2243 (cgr+), or 15644 (cgr-) into SPF mice on a 1% or 3% arginine diet three times a week for two weeks and then induced DSS colitis. Mice gavaged with E. lenta 2243 (cgr+) on a high arginine diet had decreased Th17 cells and developed less severe disease than their counterparts on a low arginine diet similar to disease severity in mice given E. lenta strain 15644 (cgr-) on either a high or low arginine diet ( Figure 5C -E, Sup. Fig 5) . This demonstrates that, in the context of colonization with a cgr+ E. lenta strain, increased arginine in the diet decreases both Th17 accumulation and colitis severity.
Discussion
The immunomodulatory effects of members of the human gut microbiota has long been appreciated and the field is now making efforts to explore the variety of mechanisms whereby these microbes influence a host's immune response. Previous studies have identified bacteria capable of increasing Th17 levels and have implicated bacterial adherence to the gut epithelial in this activation (14, 16) . While we do not rule out that E. lenta activates Th17 cells through an epithelial adhesion mechanism in addition to the effect of Cgr2 it entirely possible that a single microbe could increase Th17 cells through multiple mechanisms as seen with SFB (14, 21) . With recent studies profiling the immunomodulatory properties of a range of microbes spanning multiple phyla (16, 22) we have gained insight into how these associations could be leveraged for therapy (23) . However, it is important to note that we may be missing many microbe-immune interactions due to the strain-level differences in immune alterations. For example, rat-derived SFB does not increase Th17 cells in mice but mouse-derived SFB does (14) . This concept also applies to Bifidobacterium where B. infantis monocolonization increases Th17 cells but B. longum monocolonization does not (16) . B. infantis is a subspecies of B. longum; therefore these two bacteria share a significant overlap in their genomic content (over 97% percent identity in overlapping regions and between 9%-26% genomic content differences (BLAST)) suggesting that something in the unshared genetic material is involved in Th17 accumulation. This could be narrowed further by comparing other members of these subspecies. Thus, strain-level variations in altered immune response could provide insight into the genetic factors underlying that phenotype as seen with our findings where E. lenta strains have different capabilities to promote Th17 accumulation leading to the identification of the Cgr2 protein's involvement in this process.
Cgr2 has been previously studied for its role in reducing the heart medication digoxin into a less active by-product, dihydrodigoxin (11) . Digoxin is also a potent Th17 inhibitor and binds directly to the master transcription factor of Th17 cells, Rorγt (19, 20) while dihydrodigoxin is a less potent inhibitor (24) . However, digoxin is not normally present in the gastrointestinal tract and so the question arises whether Cgr2 is acting on an endogenous substrate. The substrate specificity of Cgr2 was recently explored and suggested that Cgr2 acts exclusively on the cardenolide class of molecules (18) . Therefore, our current hypothesis is that Cgr2 acts on an endogenous Th17 inhibitory compound that resembles digoxin such as an endogenous cardenolide (25) .
One of the major environmental factors impacting the microbiota and microbial-mediated immune modulation is the host diet. Alterations in diet significantly impact gut microbiota composition and function (9, 10) and the idea that the diet could be leveraged to manipulate the microbial immune modulation has been proposed by many researchers (26) . However, it is often difficult to assess the direct impact of dietary alterations on immune diseases from microbiotamediated effects. This is the case with dietary arginine where previous studies have shown that arginine supplementation improves disease severity in a DSS model in an iNOS dependent manner, suggesting a host mechanism of improved disease under arginine supplementation (27) .
Additionally, arginine has been well characterized to have broad impacts on immune response where the route of arginine metabolism by macrophages determines the regulatory versus inflammatory skewing of macrophage response and in T cells arginine promotes proliferation and cytokine production in response to T cell receptor (TCR) stimulation (28, 29) . However, arginine can also be metabolized by the microbiota into polyamides (30) , which have immunomodulatory functions, and can alter microbial metabolism (11) . By comparing the impact of differential arginine levels on GF and mice monocolonized with E. lenta strains we can begin to tease apart the microbial mediated versus direct impact of arginine on Th17 accumulation. Our finding that increased dietary arginine decreases E. lenta-mediated Th17 accumulation and corresponding colitis severity suggests that dietary alterations to microbial metabolism could be used to tune microbial immune modulation. However, as arginine has well established roles in inflammation and can play a pro-or anti-inflammatory role depending on its metabolism caution and careful consideration of the additional direct effects of dietary interventions must be considered.
Materials and Methods
Experimental Design. The objectives of this study were to investigate whether and how a prevalent member of the human gut microbiota, which is associated with autoimmune diseases, (2243, 1356, 15644) , a BHI media control, or no treatment (NS). IL-17a levels in the supernatant were measured via ELISA after 4 days of skewing followed by overnight PMA ionomycin restimulation (n=18-20 biological replicates (wells)/group). Levels of IL-17a are relative to the no treatment control which is set to 1. (B) In the same experimental design as A, 10 strains of E. lenta were screened and levels of IL-17a are relative to the no treatment control which is set to 1. Strains were classified into non-IL-17a inducers (fold IL-17a levels below 1) or high (fold IL-17a levels above 1). With these classifications we performed comparative genomics using ElenMatchR with 80% coverage and 80% minimum identity (17) 
